TCTMD1mon
Impella 5.5: A GameChanger for Cardiogenic Shock
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
TCTMD1mon
Acute Hemodynamic Effects of Impella 5.5 in Cardiogenic Shock and Decompensated Heart Failure on Hepatorenal Function
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Simple risk score model could help with weaning patients from mechanical circulatory support
Patients with severe heart failure or cardiogenic shock often require assistance from MCS devices such as venoarterial ...
MassDevice9d
Second Heart Assist says Whisper device caused less hemolysis compared to Abiomed Impella CP
Second Heart Assist today announced data from a study highlighting the performance of its Whisper device against a ...
Medscape5d
Cardiogenic Shock
Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at 7% to 10% during the last 25 years. Hospital mortality was about 90% in the ...
Morningstar10d
Recent Controlled Study Validates the Significantly Lower Hemolysis of the SHA Whisper Device over Impella CP
While this study utilized the Johnson & Johnson (Abiomed) Impella CP® device ... congestion (cardio-renal syndrome (CRS), and/or cardiogenic shock (CS), and those in need of prophylactic ...